Related Experiment Video
Updated: Jun 5, 2026
08:40
An Optimized Protocol to Analyze Glycolysis and Mitochondrial Respiration in Lymphocytes
Published on: November 21, 2016
Glycolytic inhibition as a strategy for developing calorie restriction mimetics
Donald K Ingram1, George S Roth
1Pennington Biomedical Research Center, LSU System, Baton Rouge, LA 70809, USA. Donald.Ingram@pbrc.edu
Experimental Gerontology
|December 21, 2010
Summary
Calorie restriction (CR) extends lifespan and healthspan. Researchers are developing calorie restriction mimetics (CRMs) to achieve similar benefits without strict dieting, exploring upstream glycolytic inhibition and downstream targets.
Area of Science:
- Gerontology
- Metabolic research
- Aging research
Background:
- Calorie restriction (CR) is a proven intervention for extending healthspan and lifespan in various models.
- Developing calorie restriction mimetics (CRMs) is a key area of gerontological research.
- CRMs aim to replicate CR's benefits without significant food intake reduction.
Purpose of the Study:
- To review the current status and future potential of various strategies for developing CRMs.
- To discuss the concept of glycolytic inhibition as an upstream approach to CRMs.
- To evaluate downstream targets for CRM development, including insulin sensitizers, sirtuin activators, and mTOR inhibitors.
Main Methods:
- Review of existing literature on calorie restriction and mimetics.
- Discussion of historical CRM candidates like 2-deoxyglucose (2DG).
- Analysis of emerging CRM strategies targeting downstream pathways.
Main Results:
- 2-deoxyglucose (2DG) showed promise as an early CRM but exhibited cardiotoxicity in rats.
- Multiple downstream targets are now being investigated for CRM development.
- Glycolytic inhibition represents an upstream strategy with potential for broader CR-like effects.
Conclusions:
- The development of CRMs is a promising field for enhancing healthspan and lifespan.
- Upstream inhibition of glycolysis may offer a broader therapeutic window than downstream targets.
- Further research is needed to identify safe and effective CRMs.
Related Concept Videos
01:19Regulation of Metabolism
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...